Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which pr...
Enregistré dans:
Autres auteurs: | Roacho-Pérez, Jorge A., Chapa, Christian, Garza Treviño, Elsa N., Delgado González, Paulina, G Buendeño, Zuca, Delgado Gallegos, Juan Luis, Sánchez Domínguez, Margarita, Sanchez Dominguez, Celia Nohemi, Islas, José Francisco |
---|---|
Format: | Artículo |
Langue: | en_US |
Publié: |
2021
|
Sujets: | |
Accès en ligne: | https://doi.org/10.3390/life11111187 https://www.mdpi.com/2075-1729/11/11/1187 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Nanoparticles for death‑induced gene therapy in cancer (Review)
par: Roacho Pérez, Jorge A
Publié: (2018) -
Nanoparticles for death‑induced gene therapy in cancer (Review)
par: Roacho Pérez, Jorge A
Publié: (2018) -
Pancreatic Cancer Treatment by Nab-Paclitaxel with Gemcitabine Combination
par: Chapa, Christian
Publié: (2022) -
A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
par: Chapa, Christian
Publié: (2022) -
Cáncer de mama. XVIII Congreso Médico Estudiantil.
par: Universidad Autónoma de Ciudad Juárez, et autres
Publié: (2017)